Hint mode is switched on Switch off
For swift navigation between sections

Statera Biopharma
LEI 5493000BKEMABEVWAK70

PDF download

Choose all Reset all
Download Cancel
Organization name
Statera Biopharma Inc (formerly Cytocom Inc)
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Statera Biopharma Inc (formerly Cytocom Inc) is a developer of therapeutic solutions intended for the treatment of autoimmune diseases. The company's patented technology spatiotemporally tuned particles add targeting and temporal control to the drug agents, thereby helping patients with a reduction in dosage frequency and side effects.

Awards

News

26/01/2023 Statera Biopharma: Material Modification To Rights Of Security Holders, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year
10/01/2023 Statera Biopharma: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And Exhibits
07/11/2022 Statera Biopharma: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities
01/11/2022 Statera Biopharma: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
18/10/2022 Statera Biopharma: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure
All organization news

Documentation

IFRS/US GAAP reports

2022
I q eng
II q eng
III q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    5493000BKEMABEVWAK70
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001318641
Registration is required to get access.